Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ceres Ventures, Inc. (CEVE)
New York City, NY, US
Ceres Ventures, Inc. is an emerging clean technology firm dedicated to developing and bringing to market innovative environmental solutions aimed at purifying contaminated water, soil, and air. The company's core technological offerings comprise: BluFlow Nanoparticles: A proprietary system that engineers and deploys tailor-made absorbent nanoparticles. These microscopic particles are designed to precisely capture and remove various contaminants and chemicals, and can also be utilized to recover valuable elements and compounds from aquatic environments. BluFlow Advanced Ultrafiltration Technology: An automated ultrafiltration process focused on reclaiming clean water from industrial waste streams and other impure liquid sources. The BluFlow Treatment System, which integrates both the Nanoparticle and Advanced Ultrafiltration technologies. This comprehensive solution effectively eliminates a broad spectrum of pollutants, compounds, and undesirable elements, rendering water sufficiently pure for potential reuse. These solutions find diverse applications, including municipal and industrial water and wastewater purification, remediation of tainted groundwater, and the extraction of valuable resources from various solutions. Previously operating as PhytoMedical Technologies, Inc., the company adopted its current name, Ceres Ventures, Inc., in November 2011. Its headquarters are located in New York, New York.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -50.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -80.69% | -72.22% | -99.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%—
-
EPS growth Medical - Care Facilities: +19.2%-102.0% Q3'12: +5.6% (vs Q3'11)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%—
-
EBIT margin Medical - Care Facilities: +11.3%—
-
ROIC Medical - Care Facilities: +6.8%— Q3'12: +232.6% (vs Q3'11)
-
Share dilution Medical - Care Facilities: +0.0%+906.0% Q3'12: +22.1% (vs Q3'11)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×-0.20× Q3'12: -0.41× (vs Q3'11)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Frank J. Fabio | Interim Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CEVE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
